

SenesTech Hires Dr. Sandra Alcaraz to Promote Regulatory Approval and Marketing of ContraPest Internationally

FLAGSTAFF, Ariz., Jan. 5, 2017 — SenesTech, Inc. (NASDAQ: SNES), a developer of novel proprietary technologies for managing animal pest populations through fertility control, today announced the hiring of Dr. Sandra Alcaraz as Vice President, Regulatory Affairs. The Company also provided further details on its international expansion strategy.

Dr. Alcaraz is experienced in biological sciences, international regulatory affairs, and the development and marketing of disruptive technologies and novel products. Dr. Alcaraz has a special expertise in launching new products that are considered “disruptive” because of their significant market impact. Most recently, Dr. Alcaraz was the Disruptive Technologies Manager for Gowan Company, a multinational developer and marketer of innovative crop protection products. Prior to that, she was a biological research scientist. Dr. Alcaraz has a bachelor’s in biology from Pontificia Universidad Javeriana in Colombia, and master’s and doctoral degrees in entomology from The Ohio State University.

“I look forward to assisting SenesTech in the registering of ContraPest worldwide, as it is truly a technology with the potential of revolutionizing rodent control practices everywhere in the world, ” said Dr. Alcaraz.

The Company also put this key addition in the context of its international expansion strategy.

“We have received EPA registration of ContraPest, a truly innovative sustainable approach to pest control. EPA registration is considered the global gold standard of regulatory approval, but, as important as the U.S. market is to us, we intend to move rapidly to address the global opportunity facing us,” said Dr. Loretta P. Mayer, Chair, CEO and co-founder of SenesTech. “While continuing to work with key customers in the U.S., we intend to increase the attention and resources we are devoting to international markets. Dr. Alcaraz will be a key contributor to pursuing opportunities to leverage our EPA registration outside the U.S.”

As has been previously disclosed, initial international efforts are likely to include South America, the United Kingdom, European Union and Australia/New Zealand, as well as the Middle East and other areas.

About SenesTech

SenesTech has developed an innovative technology for managing animal pest populations through fertility control as opposed to a lethal approach.

The Company’s first fertility control product candidate, ContraPest[®], will be marketed for use initially in controlling rat infestations. ContraPest’s novel technology and approach targets

the reproductive capabilities of both sexes, inducing egg loss in female rodents and impairing sperm development in males. Using proprietary bait stations, ContraPest is dispensed in a highly palatable liquid formulation that promotes sustained consumption by rodent communities. ContraPest is designed, formulated and dispensed to be safe for handlers and non-target species such as wildlife, livestock and pets, in a biodegradable product. In contrast, the historical approach to managing rodent pest populations, rodenticides, carries a high risk of environmental contamination and the poisoning of non-target animals, pets and children.

We believe our non-lethal approach, targeting reproduction, is more humane, less harmful to the environment, and more effective in providing a sustainable solution to pest infestations than traditional lethal pest management methods. There is currently no other non-lethal fertility control product approved by the Food and Drug Administration (FDA), or the Environmental Protection Agency (EPA), for the management of rodent populations. We believe ContraPest® will establish a new paradigm in rodent control, resulting in improved performance in rodent control over rodenticides, without the negative environmental effects of rodenticides. For more information visit the SenesTech website at www.senestech.com.

Safe Harbor Statement

This release contains "forward-looking statements" within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended and such forward-looking statements are made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. "Forward-looking statements" describe future expectations, plans, results, or strategies and are generally preceded by words such as "may," "future," "plan" or "planned," "will" or "should," "expected," "anticipates," "draft," "eventually" or "projected." You are cautioned that such statements are subject to a multitude of risks and uncertainties that could cause future circumstances, events, or results to differ materially from those projected in the forward-looking statements, including the risks that actual results may differ materially from those projected in the forward-looking statements as a result of various factors and other risks identified in our filings with the Securities and Exchange Commission. All forward-looking statements contained in this press release speak only as of the date on which they were made and are based on management's assumptions and estimates as of such date. We do not undertake any obligation to publicly update any forward-looking statements, whether as a result of the receipt of new information, the occurrence of future events or otherwise.

To view the original version on PR Newswire, visit:<http://www.prnewswire.com/news-releases/senestech-hires-dr-sandra-alcaraz-to-promote-regulatory-approval-and-marketing-of-contrapest-internationally-300386014.html>

SOURCE SenesTech, Inc.